Navigation Links
Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
Date:6/4/2008

INDIANAPOLIS, June 4 /PRNewswire/ -- Semafore Pharmaceuticals Inc. today reported interim data from a Phase I study of its lead product candidate, SF1126, a targeted pan-PI3 kinase (PI3K) inhibitor, in patients with advanced solid tumors. SF1126 is the first PI3 kinase inhibitor to be evaluated clinically in both solid tumor and multiple myeloma trials.

The data from the solid tumor trial demonstrate that SF1126 is well-tolerated in a twice-weekly I.V. infusion at exposure levels that have been shown to be active in preclinical studies. In the current trial, patients are dosed twice-weekly for four weeks, as part of a 28-day SF1126, treatment cycle. Investigators are assessing the safety, activity and pharmacokinetics of SF1126 as measured by standard response evaluation criteria in solid tumors (RECIST).

To date, 17 patients with a wide range of solid tumors have been enrolled in this multicenter, dose-cohort escalating trial, which is being conducted at T-Gen Clinical Research Services in Scottsdale, Ariz.; the Arizona Cancer Center in Tucson, Ariz.; and the IU Simon Cancer Center in Indianapolis. Stable disease has been observed in three of 12 patients who have completed at least one cycle of treatment, including a prostate, endometrial and ovarian cancer patient. Adverse events noted so far were limited to nausea, vomiting, diarrhea and rash. All adverse events have been non-cumulative and reversible. With these encouraging results, patient enrollment has accelerated, and full enrolment of the trial is anticipated by the end of the third quarter.

"As a leader in the clinical development of PI3 kinase inhibitors, we are pleased to announce this positive safety data and early signals of activity seen with SF1126," said Dennis McKeever, Semafore Pharmaceuticals' CEO. "We believe that SF1126's dual action of antitumor and antiangiogenic activity represents a step forward in delivering new therapies to cancer patients."

About SF1126
'/>"/>

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
2. Semafores SF1126 Exhibits Antitumor and Antiangiogenic Activity
3. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... York , September 22, 2014 ... (MRI) market has been recently added to Transparency Market ... (MRI) Market: Global Market Analysis, Size, Share & Forecast ... MRI market, which valued US$ 3.9 billion in 2011, ... 2011 to 2017(the forecast period of the report), and ...
(Date:9/22/2014)... 2014  Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical ... today announced it has completed three phase 3 ... Obiltoxaximab is an anti-toxin in development for the ... studies support the safety and tolerability of the ... therapeutic dose. The conclusion of these studies marks ...
(Date:9/22/2014)... -- Persistence Market Research ( http://www.persistencemarketresearch.com/ ) ... Ophthalmic Devices: Asia to Witness ... at USD 29,171.5 million in 2014 and is expected ... to 2020, to reach an estimated value of USD ... Market Study on Ophthalmic Devices:  Asia  to ...
Breaking Medicine Technology:Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 2Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 3Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Metformin, a ... risk of low levels of thyroid-stimulating hormone (TSH) among ... The researchers cautioned that low TSH levels may ... a cause-and-effect link was not established in this study. ... thyroid (hypothyroidism), there were 495 incidences of low levels ...
(Date:9/22/2014)... The “ Ztylus ” was featured on NewsWatch ... reviews and features the latest technology gadgets and services available ... expert, conducted the review and shared with viewers how it’s ... gives users four lens options for their camera. , The ... Tech Report, which reviews and features the latest technology gadgets ...
(Date:9/22/2014)... 2014 “The Race is On!” for the ... Sunday, October 12, 2014 as it moves to its new ... As the signature fundraising and awareness event for Susan G. ... Phoenix Race for the Cure provides supporters of all ages ... and even sleeping in. , “Moving the Race to ...
(Date:9/22/2014)... perspiration these symptoms are a few of the ... heart rate and plays a crucial role in its ... Aviv University points to an additional complication caused by ... Mammalian Genome , was conducted by Prof. Karen ... of Human Molecular Genetics and Biochemistry at TAU,s Sackler ...
(Date:9/22/2014)... A study led by University of North Carolina at ... the accurate diagnosis of people who are experiencing the ... delusions that define the development of severe mental disorders ... early adulthood and affects about 1 in every 100 ... person can be a life compromised, and the burden ...
Breaking Medicine News(10 mins):Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:NewsWatch Recently Featured the Phone Case “Ztylus” on National Television 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 3Health News:Lack of thyroid hormone blocks hearing development 2Health News:Blood test may help determine who is at risk for psychosis 2
... HOUSTON - A vaccine that turns the immune system ... drives the most aggressive form of glioblastoma multiforme improved ... researchers at Duke University and The University of Texas ... Journal of Clinical Oncology . Eighteen newly diagnosed ...
... Oct. 6, 2010 A set of proteins found in ... to diagnose Alzheimer,s disease, researchers at UT Southwestern Medical Center ... An analysis of the proteins, plus a clinical exam, proved ... accurate in ruling it out in people without the disease, ...
... Reinberg HealthDay Reporter , TUESDAY, Oct. 5 (HealthDay ... young adults admit they are binge drinkers, health officials said ... as having four or more drinks for women, and five ... -- numbers that are different because men and women metabolize ...
... to a discovery by a Saint Louis University researcher, scientists ... better control cholesterol levels in blood. Led by ... at Saint Louis University and published in a recent issue ... of the United States of America, the study found that ...
... New neuroscience research by life scientists from UCLA and Australia may ... to brain injury or disease. By examining how ... way the brain first captures and encodes a situation or event ... The study is published in the Sept. 29 edition ...
... By Randy Dotinga HealthDay Reporter , ... study is the latest to suggest that testosterone may ... causing serious side effects. Researchers aren,t yet ready ... to female patients. However, the treatment does hold some ...
Cached Medicine News:Health News:Vaccine extends glioblastoma patients' survival in phase II trial 2Health News:Blood test could diagnose Alzheimer's disease, UT Southwestern researchers find 2Health News:1 in 4 U.S. Teens and Young Adults Binge Drink: CDC 2Health News:1 in 4 U.S. Teens and Young Adults Binge Drink: CDC 3Health News:Better cholesterol drugs may follow Saint Louis University researcher's breakthrough 2Health News:Neuroscience research may help patients recover from brain injury 2Health News:Testosterone Could Boost Health of Heart Failure Patients 2
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... Millipore has developed a range ... to match specific water quality requirements. ... systems is designed to specifically target ... as HPLC, molecular biology and ICP-MS. ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
Medicine Products: